There has been rapid adoption of these data into guidelines such as the joint American Society of Clinical Oncology (ASCO)/Ontario Health-Cancer Care Ontario (OH-CCO) guideline, which recommends adjuvant cisplatin-based chemotherapy followed by atezolizumab in patients with resected stage II-IIIA (7th edition) NSCLC and tumours expressing PD-L1 ≥ 1% [7]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.